ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 145 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q2 2023. The put-call ratio across all filers is 1.73 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,145,994 | -35.1% | 44,853 | -27.1% | 0.00% | -50.0% |
Q2 2023 | $1,765,140 | +71.4% | 61,546 | +43.2% | 0.00% | +100.0% |
Q1 2023 | $1,030,111 | +61.9% | 42,975 | +14.5% | 0.00% | 0.0% |
Q4 2022 | $636,407 | +29.9% | 37,524 | +13.4% | 0.00% | 0.0% |
Q3 2022 | $490,000 | +25.6% | 33,087 | +33.5% | 0.00% | – |
Q2 2022 | $390,000 | -43.6% | 24,778 | -3.4% | 0.00% | -100.0% |
Q1 2022 | $692,000 | -28.1% | 25,641 | -1.4% | 0.00% | 0.0% |
Q4 2021 | $963,000 | -18.0% | 26,004 | +5.8% | 0.00% | 0.0% |
Q3 2021 | $1,174,000 | +195.0% | 24,571 | +108.5% | 0.00% | – |
Q2 2021 | $398,000 | -34.4% | 11,783 | -19.9% | 0.00% | – |
Q1 2021 | $607,000 | -71.7% | 14,702 | -70.3% | 0.00% | -100.0% |
Q4 2020 | $2,148,000 | -33.7% | 49,531 | -34.4% | 0.00% | -50.0% |
Q3 2020 | $3,240,000 | +328.0% | 75,561 | +366.0% | 0.00% | +100.0% |
Q2 2020 | $757,000 | +187.8% | 16,215 | -16.2% | 0.00% | – |
Q1 2020 | $263,000 | -59.0% | 19,359 | -67.2% | 0.00% | – |
Q4 2019 | $641,000 | – | 59,003 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SEVEN EIGHT CAPITAL, LP | 46,819 | $2,031,000 | 0.47% |
Orbimed Advisors | 1,206,886 | $49,844,000 | 0.47% |
JACOB ASSET MANAGEMENT OF NEW YORK LLC | 25,000 | $1,033,000 | 0.40% |
ARK Investment Management | 3,331,889 | $137,607,000 | 0.27% |
FEDERATED HERMES, INC. | 3,203,000 | $132,284,000 | 0.26% |
MGO ONE SEVEN LLC | 26,990 | $1,114,000 | 0.19% |
Koss-Olinger Consulting, LLC | 20,000 | $826,000 | 0.14% |
Jump Financial, LLC | 35,400 | $1,462,000 | 0.14% |
Graham Capital Management, L.P. | 74,262 | $3,067,000 | 0.14% |
New England Research & Management, Inc. | 6,005 | $248,000 | 0.14% |